NEUP (Neuphoria Therapeutics) ROC %: -22.58% (As of Mar. 2026)

What is Neuphoria Therapeutics ROC %?

Neuphoria Therapeutics NEUP +5.18% 32 ROC % is -22.58% as of Mar. 2026. GuruFocus rates NEUP with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Neuphoria Therapeutics's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was -22.58%.

As of today (2026-06-27), Neuphoria Therapeutics's WACC % is 6.80%. Neuphoria Therapeutics's ROC % is -104.80% (calculated using TTM income statement data). Neuphoria Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Neuphoria Therapeutics (NAS:NEUP) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Neuphoria Therapeutics's WACC % is 6.80%. Neuphoria Therapeutics's ROC % is -104.80% (calculated using TTM income statement data). Neuphoria Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Neuphoria Therapeutics ROC % Related Terms

Neuphoria Therapeutics ROC % Historical Data

* Premium members only.

The historical data trend for Neuphoria Therapeutics's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuphoria Therapeutics ROC % Chart

Neuphoria Therapeutics Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

ROC %

Get a 7-Day Free Trial

-43.51

-76.77

-121.21

-117.70

-2.58

Neuphoria Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROC %	Get a 7-Day Free Trial															345.01	-164.56	-165.22	-69.80	-22.58

32GF Score

Neuphoria Therapeutics Inc NEUP

ROC % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Neuphoria Therapeutics ROC % Calculation

Neuphoria Therapeutics's annualized Return on Capital (ROC %) for the fiscal year that ended in Jun. 2025 is calculated as:

	ROC % (A: Jun. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Jun. 2024 )	+	Invested Capital (A: Jun. 2025 ))	/ count )
=	-0.829 * ( 1 - 55.85% )	/	( (14.648	+	13.734)	/ 2 )
=	-0.3660035	/	14.191
=	-2.58 %

where

	Invested Capital		(A: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	27.649	-	3.636	-	( 12.608	-	max(0, 3.829	-	13.194	+	12.608	))
=	14.648

	Invested Capital		(A: Jun. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	28.59	-	4.036	-	( 14.211	-	max(0, 4.221	-	15.041	+	14.211	))
=	13.734

Neuphoria Therapeutics's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-3.308 * ( 1 - 6.48% )	/	( (13.344	+	14.059)	/ 2 )
=	-3.0936416	/	13.7015
=	-22.58 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	36.598	-	2.453	-	( 22.17	-	max(0, 2.586	-	23.387	+	22.17	))
=	13.344

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	34.809	-	1.309	-	( 19.441	-	max(0, 1.513	-	21.658	+	19.441	))
=	14.059

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -22.58% mean?

Neuphoria Therapeutics (NEUP) has a ROC % of -22.58% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Neuphoria Therapeutics and its competitors.

Is Neuphoria Therapeutics' ROC % too high?

Neuphoria Therapeutics' current ROC % is -22.58%. Overall, Neuphoria Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.

How does Neuphoria Therapeutics' ROC % compare to CRVO and IGC?

Neuphoria Therapeutics' ROC % of -22.58% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Biotechnology company?

A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Neuphoria Therapeutics and its competitors. Neuphoria Therapeutics's current ROC % is -22.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Neuphoria Therapeutics stock overvalued right now?

Neuphoria Therapeutics (NEUP) has a current ROC % of -22.58%. The current ROC % is -22.58%. Neuphoria Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For Neuphoria Therapeutics (NEUP), the current ROC % is -22.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neuphoria Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies CRVO IGC SNSE CELU DYAI KYNB SNTI NRSN SER LSTA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 100 Summit Drive, Burlington, MA, USA, 01803

Website https://www.neuphoriatx.com

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

32GF Score

Get the complete analysis for NEUP

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.53

Price

View NEUP Analysis

See ROC % data for all stocks →